Clearmind Medicine Inc. announced that it has filed a patent application with United States Patent and Trademark Office (USPTO) for the use of 3-methylmethcathinone (with the chemical name 2-(methylamino)-1-(3-methylphenyl)-1-propanon), to prevent and/or treat eating disorders either alone or in conjunction with Palmitoylethanolamide.